Keith V. Nance
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Latest Publications
- Open Access
- 1 March 2013
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 5, 101-104
Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimens
Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePathâ?¢ liquid-based pap specimens Keith V NanceDepartment of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA Recently I communicated with the Editor regarding Drs Naryshkin and Austinsâ?? article entitled "Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical carcinoma screening."1,2 As noted previously, this article is based on a single case report of squamous cell carcinoma of the cervix diagnosed in a patient who had abnormal Pap results but had negative Hybrid Capture 2 (HC2)(Qiagen NV, Hilden, Germany) high risk human papillomavirus (hrHPV) testing from SurePathâ?¢ (Becton-Dickinson, Franklin Lakes, NJ, USA) samples. The authors concluded that such testing should not be done using this collection medium. Interestingly, they also mentioned a 10% false negative rate for similar testing performed on FDA-approved Preservcyt® media on three of 31 invasive cervical carcinoma patients at Dr Austinâ??s own laboratory.View original paper by Naryshkin and Austin
- 1 March 2013
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. ume 5, 101-104
Open AccessDiagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePath™ liquid-based pap specimens
Diagnostic sensitivity for invasive cervical carcinoma of high risk HPV tests performed on SurePathâ?¢ liquid-based pap specimens Keith V NanceDepartment of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA Recently I communicated with the Editor regarding Drs Naryshkin and Austinsâ?? article entitled "Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical carcinoma screening."1,2 As noted previously, this article is based on a single case report of squamous cell carcinoma of the cervix diagnosed in a patient who had abnormal Pap results but had negative Hybrid Capture 2 (HC2)(Qiagen NV, Hilden, Germany) high risk human papillomavirus (hrHPV) testing from SurePathâ?¢ (Becton-Dickinson, Franklin Lakes, NJ, USA) samples. The authors concluded that such testing should not be done using this collection medium. Interestingly, they also mentioned a 10% false negative rate for similar testing performed on FDA-approved Preservcyt® media on three of 31 invasive cervical carcinoma patients at Dr Austinâ??s own laboratory.View original paper by Naryshkin and Austin
- Open Access
- 1 January 2013
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 5, 1-3
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening Keith V Nance Medical Directory of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
- 1 January 2013
- Published by Taylor & Francis in Drug, Healthcare and Patient Safety
- Vol. 5, 1-3
Open AccessLimitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening
Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening Keith V Nance Medical Directory of Cytology, Rex Hospital, Raleigh, and Department of Pathology, The University of North Carolina School of Medicine, Chapel Hill, NC, USA
- 15 February 2007
- Published by Wiley in Diagnostic Cytopathology
- Vol. 35 (3) , 148-153
Evolution of Pap testing at a community hospital—A ten year experience
Over a 10‐year period the Pap program at our community hospital laboratory progressed from the use of 100% conventional smears to predominantly ThinPrep® (TP) and then to nearly 100% SurePath® (SP). During this period the annual Pap volume grew from less than 20,000 to nearly 50,000. This retrospective review focuses on improvements in high‐grade squamous intraepithelial lesion (HSIL) detection rates and specimen adequacy rates during the 10‐year period.The laboratory database was used to identify 310,080 Pap test records between 1995 and 2004 inclusive. Pap type differences in HSIL detection rates and specimen adequacy rates were examined using the Cochran–Mantel–Haenszel test, with year as the stratification variable. The Breslow–Day test was used to evaluate the consistency of differences across the years. The overall results are summarized below in tabular format.Results of Combined 10‐Year Data for Total Number of Cases, HSIL Rate, and Unsatisfactory Specimen Rate by Pap Method are given: Pap Method Total Paps Total % HSIL Total % Unsat Conv Smear 128,630 0.28 0.30 ThinPrep® 88,575 0.38 0.64 SurePath® 92,875 0.50 0.17 HSIL detection rates were significantly higher for liquid‐based Pap tests compared with conventional smears (P < 0.0001). In addition, SP was associated with higher HSIL detection rates than TP with an estimated common odds ratio (OR) of 1.37 (95% confidence interval (CI), 1.10 − 1.71; P = 0.005), and higher specimen adequacy compared with TP or conventional Pap methods (P < 0.0001). Diagn. Cytopathol. 2007;35:148–153.
- 15 February 2007
- Published by Wiley in Diagnostic Cytopathology
- Vol. 35 (3) , 148-153
Evolution of Pap testing at a community hospital—A ten year experience
Over a 10‐year period the Pap program at our community hospital laboratory progressed from the use of 100% conventional smears to predominantly ThinPrep® (TP) and then to nearly 100% SurePath® (SP). During this period the annual Pap volume grew from less than 20,000 to nearly 50,000. This retrospective review focuses on improvements in high‐grade squamous intraepithelial lesion (HSIL) detection rates and specimen adequacy rates during the 10‐year period.The laboratory database was used to identify 310,080 Pap test records between 1995 and 2004 inclusive. Pap type differences in HSIL detection rates and specimen adequacy rates were examined using the Cochran–Mantel–Haenszel test, with year as the stratification variable. The Breslow–Day test was used to evaluate the consistency of differences across the years. The overall results are summarized below in tabular format.Results of Combined 10‐Year Data for Total Number of Cases, HSIL Rate, and Unsatisfactory Specimen Rate by Pap Method are given: Pap Method Total Paps Total % HSIL Total % Unsat Conv Smear 128,630 0.28 0.30 ThinPrep® 88,575 0.38 0.64 SurePath® 92,875 0.50 0.17 HSIL detection rates were significantly higher for liquid‐based Pap tests compared with conventional smears (P < 0.0001). In addition, SP was associated with higher HSIL detection rates than TP with an estimated common odds ratio (OR) of 1.37 (95% confidence interval (CI), 1.10 − 1.71; P = 0.005), and higher specimen adequacy compared with TP or conventional Pap methods (P < 0.0001). Diagn. Cytopathol. 2007;35:148–153.